Related Experiment Video
Updated: Jan 23, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies
J Solassol1, J A Vendrell2, R Senal2
1Laboratoire de Biopathologie, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France; Département de Pathologie et Oncobiologie, Laboratoire de Biologie des Tumeurs Solides, CHU Montpellier, IRCM, INSERM, Univ. Montpellier, Montpellier, France.
This study shows that lung cancer patients with BRAF V600E mutations can be treated sequentially with dabrafenib/trametinib and osimertinib. Circulating tumor DNA is crucial for monitoring treatment response alongside tissue biopsies and CT scans.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- The BRAF V600E mutation in lung adenocarcinoma presents treatment challenges.
- The efficacy of BRAF inhibitors in patients with concurrent EGFR mutations (EGFR L858R/del19, EGFR T790M) and BRAF V600E is not well-established.
Related Concept Videos
Feedback Inhibition
Enzyme Inhibition
Inhibition of Cdk Activity
Molecular Comparison of Gases, Liquids, and Solids
Rise of Liquid in a Capillary Tube
Deriving the Speed of Sound in a Liquid
The speed of sound in fluids can be derived by considering a mechanical wave...

